Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Kymera Therapeutics, Inc. Market Cap
The Kymera Therapeutics, Inc. (KYMR) share price is expected to increase by 28.22% over the next year. This is based on calculating the average 12-month share price estimate provided by 18 stock analysts who have covered KYMR. Price targets range from $38 at the low end to $90 at the high end. The current analyst consensus for KYMR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 18 Wall Street analysts have assignedKYMR 14 buy ratings, 4 hold ratings, and 0 sell ratings. This means that analysts expect Kymera Therapeutics, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KYMR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KYMR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Derek Archila Wells Fargo | Overweight | $57 | Upgrade | Dec 2, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $65 | Initiates | Nov 18, 2024 |
| James Quigley Morgan Stanley | Equal-Weight | $49 | Maintains | Nov 6, 2024 |
| Eliana Merle UBS | Buy | $74 | Maintains | Nov 4, 2024 |
Guggenheim | Buy | $52 | Maintains | Nov 1, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $53 | Reiterates | Nov 1, 2024 |
| Jeff Jones Oppenheimer | Outperform | $56 | Maintains | Sep 27, 2024 |
| Faisal Khurshid Leerink Partners | Outperform | $60 | Assumes | Sep 9, 2024 |
| Andy Chen Wolfe Research | Outperform | $65 | Upgrade | Aug 26, 2024 |
| James Quigley Morgan Stanley | Equal-Weight | $45 | Maintains | Aug 14, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $38 | Maintains | Aug 12, 2024 |
| Jeff Jones Oppenheimer | Outperform | $52 | Maintains | Jul 10, 2024 |
| Kalpit Patel B. Riley Securities | Neutral | $36 | Maintains | Jul 9, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $46 | Reiterates | Jun 17, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $46 | Reiterates | Jun 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $46 | Reiterates | May 24, 2024 |
| Jeff Jones Oppenheimer | Outperform | $52 | Maintains | May 3, 2024 |
| Jeff Jones Oppenheimer | Outperform | $53 | Initiates | Apr 22, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $54 | Maintains | Mar 1, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $56 | Maintains | Feb 27, 2024 |
When did it IPO
2020
Staff Count
184
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Market Cap
$3.09B
In 2023, KYMR generated $78.6M in revenue, which was a increase of 67.84% from the previous year. This can be seen as a signal that KYMR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 07 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Kymera Therapeutics' KT-474 is in Phase 2 trials for skin conditions, expected to complete by mid-2026. KT-621's Phase 1 data is due in H1 2025. The company has $911M cash to fund operations into mid-2027.
Why It Matters - Kymera's advancing trials and strong cash position suggest potential for growth and reduced financial risk, making it a company to watch in biotech investments.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kymera Therapeutics (NASDAQ: KYMR) will participate in fireside chats at upcoming investor events, focusing on its targeted protein degradation therapies.
Why It Matters - Kymera Therapeutics’ participation in investor events signals active engagement with the investment community, potentially increasing visibility and interest in its innovative TPD therapies.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kymera Therapeutics (NASDAQ: KYMR) will participate in fireside chats at upcoming investor events, focusing on its advancements in targeted protein degradation therapies.
Why It Matters - Kymera Therapeutics' participation in investor events signals potential new insights on its TPD advancements, impacting investor sentiment and stock performance.
Sun, 03 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Kymera Therapeutics, Inc. (NASDAQ:KYMR) will hold its Q3 2024 earnings conference call on October 31, 2024, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters - Kymera Therapeutics' Q3 earnings call provides insights into financial performance and future strategies, critical for assessing the company's growth potential and investment viability.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FDA cleared KT-621 (STAT6) for IND, and Phase 1 clinical trial dosing has begun, with data anticipated in the first half of 2025.
Why It Matters - FDA clearance and the start of dosing for KT-621 indicate progress in clinical development, potentially enhancing the company's valuation and attracting investor interest ahead of trial results.
Thu, 31 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Kymera Therapeutics (KYMR) reported a quarterly loss of $0.82 per share, slightly better than the expected loss of $0.83, and an improvement from a loss of $0.90 per share a year prior.
Why It Matters - Kymera's smaller-than-expected loss indicates improving financial performance and could boost investor confidence, potentially leading to positive stock movement.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
